Procell formerly purchased their bone marrow mesenchymal stem cell technology from the parent company of AnteAge, Cellese. But after Cellese was purchased by a private equity company, Procell no longer had access to the technology they were previously able to purchase.

To coverup the loss of this suboptimal BMSC technology from Cellese, the marketing team at Procell made a blog to spin the use of off-the-shelf technologies as something better than the technology they could no longer purchase. The private equity company that purchased Cellese/AnteAge is in the business of buying companies and then selling them for a profit. It’s not about making great products that serve mankind, it’s about making money, and lots of it. The company is proud to have “fully liquidated [one of their funds] after generating 7.2 times investors’ money, or a 59 percent annual return over 11 years – the best performance of any 2014-vintage buyout fund. That’s what they’re doing with AnteAge – cutting cost and making up much marketing hype.

And because PE doesn’t like to share, they no longer sell to poor little Procell. Now Procell has to buy technology elsewhere and has taken their suboptimal products from second-rate to third-rate.

Procell is in such a bad way that their science page still talks about bone marrow mesenchymal stem cells, even though they no longer use this technology. Sad to see the self-proclaimed “Godfather of Microchanneling” (LOL) at Procell transform into the “Vito Corleone of Maltodextrin-Infused Poking.” Yes, the “Microchanneling’s Godfather wants to make you an offer you can Refuse;” water and maltodextrin having replaced their bone marrow mesenchymal stem cell conditioned media (secretome).